Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 17/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20699399 | 0.84 | JAK3 (0.54) | SGK1CDK2JAK3 | |
| SCHEMBL20699313 | 0.81 | SGK1 (0.59) | SGK1CDK2 | |
| SCHEMBL28687735 | 0.80 | SGK1 (0.45) | SGK1CDK2JAK3 | |
| Trifluoroacetic Acid SCHEMBL20699305 | 0.74 | SGK1 (0.56) | SGK1CDK2 | |
| SCHEMBL20715202 | 0.70 | ESR1 (0.34) | SGK1 | |
| SCHEMBL28689669 | 0.69 | SGK1 (0.46) | SGK1JAK3 | |
| SCHEMBL20711965 | 0.69 | SGK1 (0.39) | SGK1JAK3 | |
| SCHEMBL28673129 | 0.68 | SGK1 (0.61) | SGK1CDK2 | |
| SCHEMBL20699308 | 0.67 | SGK1 (0.55) | SGK1CDK2 | |
| SCHEMBL20699372 | 0.67 | JAK3 (0.54) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | SGK1 96/4885CDK2 318/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.